What Is CagriSema? Research Evidence & Profile

What Is Cagrilintide + Semaglutide Blend (CagriSema)?

Cagrilintide + Semaglutide (CagriSema) is a named combination blend that brings together cagrilintide and semaglutide as separate peptide components. This page identifies the material as Cagrilintide + Semaglutide Blend (CagriSema). The Cagrilintide + Semaglutide (CagriSema) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

This is a multi-component catalogue blend, so a single molecular formula, molecular weight or CAS number is not assigned to the combined product.

Evidence at a Glance

31ClinicalTrials.gov query records

73PubMed query records

6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for Cagrilintide + Semaglutide (CagriSema) is organized around combination-peptide comparison, amylin and GLP-1 pathway literature, ligand profiling workflows, and analytical blend characterization. For Cagrilintide + Semaglutide (CagriSema), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
NCT05669755REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels	Phase 3	Active Not Recruiting	Cardiovascular Disease	2026-08-31
NCT06534411A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both	Phase 3	Completed	Diabetes Mellitus, Type 2	2026-09-09
NCT06289504A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight	Phase 1	Completed	Obesity	2026-05-19
NCT06221969A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor	Phase 3	Completed	Type 2 Diabetes	2026-09-04
NCT05567796A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight	Phase 3	Active Not Recruiting	Obesity	2026-09-30
NCT06403761Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes	Phase 1	Completed	Diabetes Mellitus, Type 2	2026-02-27

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.

BMJ (Clinical research ed.) · 2024 Jan 29

PMID 38286487

Selected PubMed record

Emerging pharmacotherapies for obesity: A systematic review.

Pharmacological reviews · 2025 Jan

PMID 39952695

Selected PubMed record

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

The New England journal of medicine · 2025 Aug 14

PMID 40544433

Selected PubMed record

Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.

Diabetes, obesity & metabolism · 2026 Oct

PMID 42503495

Selected PubMed record

Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

The New England journal of medicine · 2025 Aug 14

PMID 40544432

Selected PubMed record

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.

Indian journal of endocrinology and metabolism · 2024 Sep-Oct

PMID 39676787

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: Cagrilintide + Semaglutide Blend (CagriSema)
Available Specifications: 5mg, 10mg
Pack Format: 10 Vials

This is a multi-component catalogue blend, so a single molecular formula, molecular weight or CAS number is not assigned to the combined product.

Source: NOVABIO product identity record · No single PubChem record is asserted for this catalogue entry.

Research Tools for Cagrilintide + Semaglutide Blend (CagriSema)

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Cagrilintide + Semaglutide Blend (CagriSema) Research Summary

Identity

Cagrilintide + Semaglutide Blend (CagriSema); specifications: 5mg, 10mg. This is a multi-component catalogue blend, so a single molecular formula, molecular weight or CAS number is not assigned to the combined product.

Mechanism

Evidence

31 registry records and 73 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Cagrilintide + Semaglutide Blend (CagriSema) is represented here by the catalogue identity Cagrilintide + Semaglutide Blend (CagriSema). This is a multi-component catalogue blend, so a single molecular formula, molecular weight or CAS number is not assigned to the combined product. The product record lists 5mg, 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for Cagrilintide + Semaglutide (CagriSema) is organized around combination-peptide comparison, amylin and GLP-1 pathway literature, ligand profiling workflows, and analytical blend characterization. For Cagrilintide + Semaglutide (CagriSema), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 31 ClinicalTrials.gov records and 73 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Cagrilintide + Semaglutide Blend (CagriSema) FAQ

What is Cagrilintide + Semaglutide Blend (CagriSema)?

What research records are indexed for Cagrilintide + Semaglutide Blend (CagriSema)?

The synchronized query returned 31 ClinicalTrials.gov records and 73 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Cagrilintide + Semaglutide Blend (CagriSema) FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.